|Bid||0.5821 x 900|
|Ask||0.6200 x 1000|
|Day's Range||0.5781 - 0.6500|
|52 Week Range||0.2300 - 2.4600|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2023 - Feb 17, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the